Mumbai, September 02, 2014 – Cipla LtdBSE 5.23 % has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc’s Advair, a move that will further dent sales of the British firm’s top-selling product.
Cipla’s drug will be marketed under the name Serrofloin in Germany and Salmeterol/Fluticasone Cipla in Sweden, the Mumbai-based company said in a statement on Monday.
Making copies of inhaled drugs such as Advair is a challenge because of the complexity of making a device that effectively delivers the medicine directly into the lungs. Business Line
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…